Heart Health

This news channel includes content on cardiovascular disease prevention, cardiac risk stratification, diagnosis, screening programs, and management of major risk factors that include diabetes, hypertension, diet, life style, cholesterol, obesity, ethnicity and socio-economic disparities.

Dexcom issues new recall for CGM apps due to safety risk—users urged to update immediately
The FDA has categorized this as a Class I recall. If patients update their phone or watch apps as needed, they can continue to use these devices like normal.
Plant-based diets linked to lower risks of death, heart disease, stroke and diabetes
Diets that prioritize plant-based foods are associated with several health benefits, according to a new study of more than 3.4 million adults. Such diets also show potential to reduce greenhouse gas emissions.
Health systems use AI to target patients who may have elevated Lp(a) levels
"We can start helping people right now, and it would be meaningful if we can raise more awareness to reduce the burden of CVD," explained Katherine Wilemon, founder and CEO of the Family Heart Foundation.
Oral GLP-1 drug linked to weight loss in patients with and without diabetes—is FDA approval next?
Eli Lilly and Company is back with even more positive data on orforglipron, its oral GLP-1 receptor agonist. The company says it is "moving with urgency" toward gaining key regulatory approvals and getting the drug in the hands of patients.
Cardiology group thanks Taylor Swift for spreading word about nuclear stress testing
When Taylor Swift speaks, the world listens. And when she recently appeared on a podcast for the very first time, she shared the story of how a nuclear stress test saved her father's life.

Seth Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC, Chairman of the Board for the Family Heart Foundation, past president of the American Society for Preventive Cardiology, clinical affiliate professor of biomedical science at Florida Atlantic University, and chief medical officer of Flourish Research, explains why testing for familial hypercholesterolemia (FH) and elevated Lipoprotein(a) could be critical to identify more patients with elevated risk of cardiac events, but have their LDL well controlled.

Lipoprotein(a) tests could transform patient care—is it time for universal screening?

"Lp(a) represents the most important potential potential paradigm shift in cardiovascular disease prevention that we'll experience over the next five to 10 years," Seth Baum, MD, explained in a new interview.

Researchers use wearable fitness trackers to monitor sleep, CVD risk

A new two-year study is focused on the potential of using commercially available fitness trackers to identify patients who may face an increased risk of CVD.

AHA Cardiovascular-Kidney-Metabolic Health Initiative regions as of July 2025.

AHA expands efforts to spread the word about CKM syndrome

This is a rapidly growing area of interest in cardiology as research continues to find close links between heart disease and kidney disease.

weight loss scale overweight obese lose weight pounds

Another win for Lilly: Oral GLP-1 drug linked to significant weight loss, other cardiovascular benefits

Tirzepatide and semaglutide are getting the attention now, but orforglipron could be the next go-to drug for patients hoping to lose weight and improve their heart health—no injections required.

Wildfire pollution image. Photo courtesy of the American Heart Association.

Air purifiers may reduce cardiovascular risks from pollution and wildfires

Multiple studies in recent years have linked poor air quality to significant cardiac risks. Air filters, however, have shown potential to help combat these risks.

Too much screen time is bad for the heart

The excessive use of electronic devices is associated with significant health risks for young children and adolescents. In fact, too much screen time may impact the body in ways that last well into adulthood.

Tirzepatide, a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide receptor agonist (GLP-1), has been approved by the U.S. Food & Drug Administration (FDA) for improving glycemic control among adults with type 2 diabetes. The medication, sold by Eli Lilly and Company under the name Mounjaro, will be available in six different doses and come in an auto-injector pen.

Tirzepatide demonstrates cardiovascular protection in head-to-head trial with dulaglutide

Tirzepatide met the primary endpoint of non-inferiority versus dulaglutide, with an 8% lower rate of MACE events included cardiovascular death, heart attack or stroke, while delivering greater reductions in A1C and weight.

cannabis weed marijuana heart health doctor cardiologist

Smoking cannabis may not impact heart health of older CAD patients

Researchers explored data from thousands of U.S. veterans with coronary artery disease, sharing their findings in Circulation.

Heart Health

Dexcom issues new recall for CGM apps due to safety risk—users urged to update immediately

Plant-based diets linked to lower risks of death, heart disease, stroke and diabetes

Health systems use AI to target patients who may have elevated Lp(a) levels

Oral GLP-1 drug linked to weight loss in patients with and without diabetes—is FDA approval next?

Cardiology group thanks Taylor Swift for spreading word about nuclear stress testing